Modulation of cell sensitivity to antitumor agents by targeting survival pathways

Biochemical Pharmacology

Volumn 80, Issue 10, 2010, Pages 1459-1465

  Perego, Paola ^a   Cossa, Giacomo ^a   Zuco, Valentina ^a   Zunino, Franco ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Antitumor agents; Drug combinations; Survival pathways; Targeted therapy

Indexed keywords

CISPLATIN; HEAT SHOCK PROTEIN 90; LAPATINIB; PLATINUM DERIVATIVE; TAXANE DERIVATIVE; TRASTUZUMAB; ANTINEOPLASTIC AGENT; MITOGEN ACTIVATED PROTEIN KINASE; MTOR PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN SERINE THREONINE KINASE; SIGNAL PEPTIDE; TARGET OF RAPAMYCIN KINASE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CARCINOGENESIS; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CELL HYPOXIA; CELL PROLIFERATION; CELL SURVIVAL; DRUG EFFICACY; DRUG TARGETING; HUMAN; NOTE; OXIDATIVE STRESS; PRIORITY JOURNAL; ANIMAL; DRUG DESIGN; DRUG EFFECTS; DRUG RESISTANCE; ENDOPLASMIC RETICULUM; ENZYMOLOGY; METABOLISM; NEOPLASMS; PATHOLOGY; TUMOR CELL LINE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; DRUG DESIGN; DRUG RESISTANCE, NEOPLASM; ENDOPLASMIC RETICULUM; HSP90 HEAT-SHOCK PROTEINS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MITOGEN-ACTIVATED PROTEIN KINASES; NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PHOSPHATIDYLINOSITOL 3-KINASES; TOR SERINE-THREONINE KINASES;

EID: 77957017281     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2010.07.030     Document Type: Note

References (98)

1. Janne P.A., Gray N., Settleman J. Factors underlying sensitivity of cancers to small-molecule kinase inhibitors. Nat Rev 2009, 8:709-723.
2. Engelman J.A., Settleman J. Acquired resistance to tyrosine kinase inhibitors during cancer therapy. Curr Opin Genet Dev 2008, 18:73-79.
3. Courtney K.D., Corcoran R.B., Engelman J.A. The PI3K pathway as drug target in human cancer. J Clin Oncol 2010, 28:1075-1083.
4. Liu P., Cheng H., Roberts T.M., Zhao J.J. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 2009, 8:627-644.
5. Yuan T.L., Cantley L.C. PI3K pathway alterations in cancer: variations on a theme. Oncogene 2008, 27:5497-5510.
6. Workman P., Clarke P.A., Raynaud F.I., van Montfort R.L.M. Drugging the PI3 kinome: from chemical tools to drugs in the clinic. Cancer Res 2010, 70:2146-2157.
7. Bai D., Ueno L., Vogt P.K. Akt-mediated regulation of NFkB and the essentialness of NFkB for the oncogenicity of PI3K and Akt. Int J Cancer 2009, 125:2863-2870.
8. Heffeter P., Jungwirth U., Jakupec M., Hartinger C., Galanski M., Elbling L., et al. Resistance against novel anticancer metal compounds: differences and similarities. Drug Resist Updat 2008, 11:1-16.
9. Guertin D.A., Sabatini D.M. Defining the role of mTOR in cancer. Cancer Cell 2007, 12:9-22.
10. Gunn R.M., Hailes H.C. Insights into the PI3-K-PKB-mTOR signalling pathway from small molecules. J Chem Biol 2008, 1:49-62.
11. Fan Q., Fan Q.W., Knight Z.A., Goldenberg D.D., Yu W., Mostov K.E., et al. A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 2006, 9:341-349.
12. Yao E., Zhou W., Lee-Hoeflich S.T., Truong T., Haverty P.M., Eastham-Anderson J., et al. Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab. Clin Cancer Res 2009, 15:4147-4156.
13. Fujiwara M., Izuishi K., Sano T., Hossain M.A., Kimura S., Masaki T., et al. Modulating effect of the PI3-kinase inhibitor LY294002 on cisplatin in human pancreatic cancer cells. J Exp Clin Cancer Res 2008, 27:76-85.
14. Liu L.-Z., Zhou X.-D., Qian G., Shi X., Fang J., Jiang B.-H. Akt1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamycin/p70S6K1 pathway. Cancer Res 2007, 67:632532.
15. Kim D., Cheng G.Z., Lindsley C.W., Yang H., Cheng J.Q. Targeting the phosphatidylinositol-3 kinase/Akt pathway for the treatment of cancer. Curr Opin Invest Drugs 2005, 6:1250-1258.
16. Zhang H.Y., Zhang P.N., Sun H. Aberration of the PI3K/Akt/mTOR signalling in epithelial ovarian cancer and its implication in cisplatin-based chemotherapy. Eur J Obstet Gynecol Reprod Biol 2009, 146:81-86.
17. Yu K., Toral-Barza L., Shi C., Zhang W.C., Lucas J., Shor B., et al. Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin. Cancer Res 2009, 69:6232-6240.
18. Wangpaichitr M., Wu C., You M., Kuo M.T., Feun L., Lampidis T., et al. Inhibition of mTOR restores cisplatin sensitivity through down-regulation of growth and anti-apoptotic proteins. Eur J Pharmacol 2008, 591:124-127.
19. Tam K.H., Yang Z.F., Lau C.K., Lam C.T., Pang R.W.C., Poon R.T.P. Inhibition of mTOR enhances chemosensitivity in hepatocellular carcinoma. Cancer Lett 2009, 273:201-209.
20. Leelawat K., Narong S., Udomchaiprasertkul W., Leelawat S., Tungpradubkul S. Inhibition of PI3K increases oxaliplatin sensitivity in cholangiocarcinoma cells. Cancer Cell Int 2009, 9:3-10.
21. Marinov M., Ziogas A., Pardo O.E., Tan L.T., Dhillon T., Mauri F.A., et al. Akt/mTOR pathway activation and BCL-2 family proteins modulate the sensitivity of human small cell lung cancer cells to RAD001. Clin Cancer Res 2009, 15:1277-1287.
22. Aissat N., Le Tourneau C., Ghoul A., Serova M., Bieche I., Lokiec F., et al. Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines. Cancer Chemother Pharmacol 2008, 62:305-313.
23. Tsuchida R., Das B., Yeger H., Koren G., Shibuya M., Thorner P.S., et al. Cisplatin treatment increases survival and expansion of a highly tumorigenic side-population fraction by upregulating VEGF/Flt1 autocrine signaling. Oncogene 2008, 27:3923-3934.
24. Winograd-Katz S.E., Levitzki A. Cisplatin induces PKB/Akt activation and p38MAPK phosphorylation of the EGF receptor. Oncogene 2006, 25:7381-7390.
25. Eichhorn P.J., Gili M., Scaltriti M., Serra V., Guzman M., Nijkamp W., et al. Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resitance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res 2008, 68:9221-9230.
26. Vazquez-Martin A., Oliveras-Ferraros C., del Barco S., Martin-Castillo B., Menéndez J.A. mTOR inhibitors and the anti-diabetic biguanide metformin: new insights into the molecular management of breast cancer resistance to the HER2 tyrosine kinase inhibitor lapatinib (Tykerb). Clin Transl Oncol 2009, 11:455-459.
27. Berns K., Horlings H.M., Hennessy B.T., Madiredjo M., Hijmans E.M., Beelen K., et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resitance in breast cancer. Cancer Cell 2007, 12:295-402.
28. Li T., Wang J., Wang X., Yang N., Chen S., Tong L., et al. WJD008, a dual PI3K/mTOR inhibitor, prevents PI3K signalling and inhibits the proliferation of transformed cells with oncogenic PI3K mutant. J Pharmacol Exp Ther 2010, 334:830-838.
29. Zitzmann K., von Ruden J., Brand S., Goke B., Lichtl J., Spottl G., et al. Compensatory activation of Akt in response to mTOR and Raf inhibitors-a rationale for dual-targeted therapy approaches in neuroendocrine tumor disease. Cancer Lett 2010, 295:100-109.
30. Zakikhani M., Blouin M.J., Piura E., Pollak M.N. Metformin and rapamycin have distinct effects on the Akt pathway and proliferation in breast cancer cells. Breast Cancer Res Treat 2010, 123:271-279.
31. Petrangolini G., Pratesi G., De Cesare M., Supino R., Pisano C., Marcellini M., et al. Antiangiogenic effects of the novel camptothecin ST1481 (Gimatecan) in human tumor xenografts. Mol Cancer Res 2003, 1:863-870.
32. Pisano C., De Cesare M., Beretta G.L., Zuco V., Pratesi G., Penco S., et al. Preclinical profile of antitumor activity of a novel hydrophilic camptothecin, ST1968. Mol Cancer Ther 2008, 7:2051-2059.
33. Brozovic A., Osmak M. Activation of mitogen-activated protein kinases by cisplatin and their role in cisplatin-resistance. Cancer Lett 2007, 251:1-16.
34. Persons D.L., Yazlovitskaya E.M., Cui W., Pelling J.C. Cisplatin-induced activation of mitogen-activated protein kinases in ovarian carcinoma cells: inhibition of extracellular signal-regulated kinase activity increases sensitivity to cisplatin. Clin Cancer Res 1999, 5:1007-1014.
35. Hayakawa J., Ohmichi M., Kurachi H., Ikegami H., Kimura A., Matsuoka T., et al. Inhibition of extracellular signal-regulated protein kinase or c-Jun N-terminal protein kinase cascade, differentially activated by cisplatin, sensitizes human ovarian cancer cell line. J Biol Chem 1999, 274:31648-31654.
36. Wang X., Martindale J.L., Holbrook N.J. Requirement for ERK activation in cisplatin-induced apoptosis. J Biol Chem 2000, 275:39435-39443.
37. Benedetti V., Perego P., Beretta G.L., Corna E., Tinelli S., Righetti S.C., et al. Modulation of serviva pathways in ovarian carcinoma cell lines resistant to platinum compounds. Mol Cancer Ther 2008, 7:679-687.
38. Zanchi C., Zuco V., Lanzi C., Supino R., Zunino F. Modulation of survival signaling pathways and persistence of the genotoxic stress as a basis for the synergistic interaction between the atypical retinoid ST1926 and the epidermal growth factor receptor inhibitor ZD1839. Cancer Res 2005, 65:2364-2372.
39. Zuco V., Zanchi C., Cassinelli G., Lanzi C., Supino R., Pisano C., et al. Induction of apoptosis and stress response in ovarian carcinoma cell lines treated with ST1926, an atypical retinoid. Cell Death Differ 2004, 11:280-289.
40. Tsai J., Lee J.T., Wang W., Zhang J., Cho H., Mamo S., et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. PNAS 2008, 105:3041-3046.
41. Sheperd C., Puzanov I., Sosman J.A. B-RAF inhibitors: an evolving role in the therapy of malignant melanoma. Curr Oncol Rep 2010, 12:146-152.
42. Poulikakos P.I., Zhang C., Bollag G., Shokat K.M., Rosen N. RAF inhibitors transactivate RAF dimmers and ERK signalling in cells with wild-type BRAF. Nature 2010, 464:427-430.
43. Solit D.B., Garraway L.A., Pratilas C.A., Sawai A., Getz G., Basso A., et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 2006, 439:358-362.
44. Wee S., Jagani Z., Xiang K.X., Loo A., Dorsch M., Yao Y.M., et al. P13K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. Cancer Res 2009, 69:4286-4293.
45. Engelman J.A., Chen L., Tan X., Crosby K., Guimaraes A.R., Upadhyay R., et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 2008, 14:1351-1356.
46. Grant S. Cotargeting survival signalling pathways in cancer. J Clin Invest 2008, 118:3003-3006.
47. Pratesi G., Perego P., Zunino F. Role of Bcl-2 and its post-transcriptional modification in response to antitumor therapy. Biochem Pharmacol 2001, 61:381-386.
48. Ni Chonghaile T., Letai A. Mimicking the BH3 domain to kill cancer cells. Oncogene 2009, 27:S149-S157.
49. Keuling A.M., Andrew S.E., Tron V.A. Inhibition of p38 MAPK enhances ABT-737-induced cell death in melanoma cell lines: novel regulation of PUMA. Pigment Cell Melanoma Res 2010, 23:430-440.
50. Porter J.R., Fritz C.C., Depew K.M. Discovery and development of Hsp90 inhibitors: a promising pathway for cancer therapy. Curr Opin Chem Biol 2010, 14:1-9.
51. Whitesell L., Lindquist S.L. Hsp90 and the chaperoning of cancer. Nat Rev Cancer 2005, 5:761-772.
52. Wandinger S.K., Richter K., Buchner J. The Hsp90 chaperone machinery. J Biol Chem 2008, 283:18473-18477.
53. Bali P., Pranpat M., Bradner J., Balasis M., Fiskus E., Guo F., et al. Inhibition of histone deacetylase 6 acetylase and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem 2005, 280:26729-26734.
54. Porter J.R., Fritz C.C., Depew K.M. Discovery and development of Hsp90 inhibitors: a promising pathway for cancer therapy. Curr Opin Chem Biol 2010, 14:412-420.
55. Workman P., Burrows F., Neckers L., Rosen N. Drugging the cancer chaperone HSP90. Combinatorial therapeutic exploitation of oncogene addiction and tumor stress. Ann NY Acad Sci USA 2007, 1113:202-316.
56. Wong C., Chen S. Heat shock protein 90 inhibitors: new mode of therapy to overcome endocrine resistance. Cancer Res 2009, 69:8670-8677.
57. Sain N., Krishnan B., Ormerod M.G., De Rienzo A, Liu W.M., Kaye S.B., et al. Potentiation of paclitaxel activity by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated Akt. Mol Cancer Ther 2006, 5:1197-1208.
58. Sawai A., Chandarlapaty S., Greulich H., Gonen M., Ye Q., Arteaga C.L., et al. Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel. Cancer Res 2008, 68:589-596.
59. Beretta G.L., Gatti L., Corna E., Carenini N., Zunino F., Perego P. Defining targets of modulation of human tumor cell response to cisplatin. J Inorg Biochem 2008, 102:1406-1415.
60. Castagna A., Antonioli P., Astner H., Hamdan M., Righetti S.C., Perego P., et al. A proteomic approach to cisplatin resistance in the cervix squamous cell carcinoma cell line A431. Proteomics 2004, 4:3246-3267.
61. Gatti L., Chen D., Beretta G.L., Rustici G., Carenini N., Corna E., et al. Global gene expression of fission yeast in response to cisplatin. Cell Mol Life Sci 2004, 61:2253-2263.
62. Ali M.M., Roe S.M., Vaughan C.K., Meyer P., Panaretou B., Piper P.W., et al. Crystal structure of an Hsp90-nucleotide-p23/Sba1 closed chaperone complex. Nature 2006, 440:1013-1017.
63. Hudson C.C., Liu M., Chiang G.G., Otterness D.M., Loomis D.C., Kaper F., et al. Regulation of hypoxia-inducible factor 1α expression and function by the mammalian target of rapamycin. Mol Cell Biol 2002, 22:7004-7014.
64. Harada H., Itasaka S., Kizaka-Kondoh S., Shibuya K., Morinibu A., Shinomiya K., et al. The Akt/mTOR pathway assures the synthesis of HIF-1α protein in a glucose- and reoxygenation-dependent manner in irradiated tumors. J Biol Chem 2009, 284:5332-5342.
65. Zhou J., Schmid T., Frank R., Brune B. PI3K/Akt is required for heat shock proteins to protect hypoxia-inducible factor 1α from pVHL-independent degradation. J Biol Chem 2004, 279:13506-13513.
66. Sullivan R., Paré G.C., Frederiksen L.J., Semenza G.L., Graham C.H. Hypoxia-induced resistance to anticancer drugs is associated with decreased senescence and requires hypoxia-inducible factor-1 activity. Mol Cancer Ther 2008, 7:1961-1973.
67. Toschi A., Lee E., Gadir N., Ohh M., Foster D.A. Differential dependence of hypoxia-inducible factors 1 alpha and 2 alpha on mTORC1 and mTORC2. J Biol Chem 2008, 283:34495-34499.
68. Kroemer G., Pouyssegur J. Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 2008, 13:472-482.
69. Semenza G.L. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003, 3:721-732.
70. Tennant D.A., Duran R.V., Gottlieb E. Targeting metabolic transformation for cancer therapy. Nat Rev Cancer 2010, 10:267-277.
71. Sahra I.B., Laurent K., Giuliano S., Larbret F., Ponzio G., Gounon P., et al. Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells. Cancer Res 2010, 70:2465-2475.
72. Wang W., Guan K.-L. AMP-activated protein kinase and cancer. Acta Physiol 2009, 196:55-63.
73. Kisfalvi K., Eibl G., Sinnett-Smith J., Rozengurt E. Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth. Cancer Res 2009, 69:6539-6545.
74. Simons A.L., Fath M.A., Mattson D.M., Smith B.J., Walsh S.A., Graham M.M., et al. Enhanced response of human head and neck cancer, xenograft tumors to cisplatin combined with 2-deoxy-d-glucose correlates with increased 18F-FDG uptake as determined by PET imaging. Int J Radiat Oncol Biol Phys 2007, 69:1222-1230.
75. Zhang F., Aft R.L. Chemosensitizing and cytotoxic effects of 2-deoxy-d-glucose on breast cancer cells. J Cancer Res Ther 2009, 1:S41-S43.
76. De Cesare M., Pratesi G., Giusti A., Polizzi D., Zunino F. Stimulation of the apoptotic response as a basis for the therapeutic synergism of lonidamine and cisplatin in combination in human tumour xenografts. Br J Cancer 1998, 77:434-439.
77. Pratesi G., De Cesare M., Zunino F. Efficacy of lonidamine combined with different DNA-damaging agents in the treatment of the MX-1 tumor xenograft. Cancer Chemother Pharmacol 1996, 38:123-128.
78. Di Cosimo S., Ferretti G., Papaldo P., Carlini P., Fabi A., Cognetti F. Lonidamine: efficacy and safety in clinical trials for the treatment of solid tumors. Drugs Today 2003, 39:157-174.
79. Loar P., Wahl H., Kshirsagar M., Gossner G., Griffith K., Liu J.R. Inhibition of glycolysis enhances cisplatin-induced apoptosis in ovarian cancer cells. Am J Obstet Gynecol 2010, 202:371.
80. Wangpaichitr M., Savaraj N., Maher J., Kurtoglu M., Lampidis T.J. Intrinsically lower Akt, mammalian target of rapamycin, and hypoxia-inducible factor activity correlates with increased sensitivity to 2-deoxy-d-glucose under hypoxia in lung cancer cell lines. Mol Cancer Ther 2008, 7:1506-1513.
81. Maher J.C., Wangpaichitr M., Savaraj N., Kurtoglu M., Lampidis T.J. Hypoxia-inducible factor-1 confers resistance to the glycolytic inhibitor 2-deoxy-d-glucose. Mol Cancer Ther 2007, 6:732-741.
82. Ramanathan A., Schreiber S.L. Direct control of mitochondrial function by mTOR. PNAS 2009, 106:22229-22232.
83. Healy S.J.M., Gorman A.M., Mousavi-Shafaei P., Gupta S., Samali A. Targeting the endoplasmic reticulum-stress response as an anticancer strategy. Eur J Pharmacol 2009, 625:234-246.
84. Rouschop K.M.A., van den Beucken T., Dubois L., Niessen H., Bussink J., Savelkouls K., et al. The unfolded protein response protects human tumor cells during hypoxia thorugh regulation of the autophagy genes MAP1LC3B and ATG5. J Clin Invest 2010, 120:127-141.
85. Saito S., Furuno A., Sakurai J., Sakamoto A., Park H.-R., Shin-ya K., et al. Chemical genomics identifies the unfolded protein response as a target for selective cancer cell killing during glucose deprivation. Cancer Res 2009, 69:4225-4234.
86. Kawaguchi Y., Kovacs J.J., McLaurin A., Vance J.M., Ito A., Yao T.P. The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell 2003, 115:727-738.
87. Bots M., Johnstone R.W. Rational combinations using HDAC inhibitors. Clin Cancer Res 2009, 15:3970-3977.
88. Giommarelli C., Zuco V., Favini E., Pisano C., Dal Piaz F., De Tommasi N., et al. The enhancement of antiproliferative and proapoptotic activity of HDAC inhibitors by curcumin is mediated by Hsp90 inhibition. Cell Mol Life Sci 2010, 67:995-1004.
89. Reuter S., Eifes S., Dicato M., Aggarwal B.B., Diederich M. Modulation of anti-apoptotic and survival pathways by curcumin as a strategy to induce apoptosis in cancer cells. Biochem Pharmacol 2008, 76:1340-1351.
90. Rao R., Nalluri S., Kolhe R., Yang Y., Fiskus W., Chen J., et al. Treatment with panobinostat induces glucose-regulated protein 78 acetylation and endoplasmic reticulum stress in breast cancer cells. Mol Cancer Ther 2010, 9:942-952.
91. Kahali S., Sarcar B., Fang B., Williams E.S., Koomen J.M., Tofilon P.J., et al. Activation of the unfolded protein response contributes toward the antitumor activity of vorinostat. Neoplasia 2010, 12:80-86.
92. Park H.R., Tomida A., Sato S., Tsukumo Y., Yun J., Yamori T., et al. Effect on tumor cells of blocking survival response to glucose deprivation. J Natl Cancer Inst 2004, 96:1300-1310.
93. Hirsch H.A., Iliopoulos D., Tsichlis P.N., Struhl K. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res 2009, 69:7507-7511.
94. Giommarelli C., Corti A., Supino R., Favini E., Paolicchi A., Pompella A., et al. γ-Glutamyltransferase-dependent resi stance to arsenic trioxide in melanoma cells and cellular sensitization by ascorbic acid. Free Rad Biol Med 2009, 46:1516-1526.
95. Bao R., Lai C.-J., Wang D.-G., Qu H., Yin L., Zifcak B., et al. Targeting heat shock protein 90 with CUDC-305 overcomes erlotinib resistance in non-small cell lung cancer. Mol Cancer Ther 2009, 8:3296-3306.
96. Ghayad S.E., Vendrell J.A., Ben Larbi S., Dumontet C., Bieche I., Cohen PA Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways. Int J Cancer 2010, 126:545-562.
97. Pisano C., Vesci L., Milazzo F.M., Guglielmi M.B., Foderà R., Barbarino M., et al. Metabolic approach to the enhancement of antitumor effect of chemotherapy: a key role of acetyl-l-carnitine. Clin Cancer Res 2010, 16:3944-3953.
98. Dancey J.E., Chen H.X. Strategies for optimizing combinations of molecularly targeted anticancer agents. Nat Rev Drug Discov 2006, 5:649-659.